Aetion.Schneew.Head2Sebastian Schneeweiss, M.D., Sc.D.

Selected PublicationsHarvard Catalyst

Brigham & Women’s Hospital
Department of Medicine
Division of Pharmacoepidemiology & Pharmacoeconomics
1620 Tremont Street, Suite 3030,
Boston, MA 02120

sschneeweiss@partners.org
Phone: 617-278-0930 | Fax: 617-232-8602

Assistant: Ms. Paula Cole, pcole1@partners.org


Sebastian Schneeweiss is Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine of the Brigham and Women’s Hospital. He is a Professor of Medicine at Harvard Medical School and Professor in Epidemiology at the Harvard  School of Public Health.

Dr. Schneeweiss’ work focuses on the comparative effectiveness and safety of biopharmaceuticals and analytic methods to improve the validity of findings from epidemiologic studies using complex healthcare databases. He is particularly interested in newly marketed medications and how real-world evidence can be generated expeditiously without sacrificing the accuracy of findings. He applies computationally intensive algorithms to large healthcare databases to improve confounding control in non-randomized studies supporting causal inference.  Automatization of these analytics in order to generate new evidence in rapid cycles is part of his focus. Disease areas of interest include cardiovascular, antithrombotic therapy, rheumatology, mental health, and others.

He is Principal Investigator of the Harvard-Brigham Drug Safety Research Center funded by FDA/CDER. His research is funded by multiple NIH grants. Dr. Schneeweiss is Past President of the International Society for Pharmacoepidemiology and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology. He is voting consultant to the FDA Drug Safety and Risk Management Advisory Committee and past inaugural member of the Methods Committee of the Patient Centered Outcomes Research Institute.

He received his medical training at the University of Munich Medical School and his doctoral degree in Pharmacoepidemiology from Harvard.

Current Courses Taught

EPI286 Database Analytics in Pharmacoepidemiology (Fall 2016) – This course is intended primarily for graduate students considering a career in the pharmaceutical/biotech industry, pharmaceutical benefits management, or in national regulatory bodies. Students will learn to design, implement and interpret pharmacoepidemiologic studies using longitudinal healthcare databases. (Dr. Schneeweiss, Dr. Gagne)

EPI253 Effectiveness Research with Longitudinal Healthcare Databases (Summer 2016) – The target audience consists of researchers working in academia, medical product industry, health plans, government institutions, regulatory agencies, who have access to large longitudinal healthcare databases. They may use such data to evaluate the effectiveness of medical interventions and care patterns, to understand the comparative effectiveness and safety of medical products (drugs, devices), to test the impact of coverage policy changes, or to monitor the outcome of risk-sharing arrangements. (Dr. Schneeweiss, Dr. Fischer, Dr. Hernandez-Diaz)

EPI235 Epi Methods in Health Services Research (Spring 2014) – The course is designed to introduce students to the application of standard epidemiologic methods to Health Services Research. Students will learn to recognize the principles of Epidemiology in Health Services Research and understand the terminology and methods specific to the field. (Dr. Polinski, Dr. Schneeweiss)

Selected Publications | Current PubMed Search Results